Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Are there income restrictions for lipitor's patient program?How does lurbinectedin increase targeting accuracy in therapy?What is the expiration date for opdivo's patent?Losartan atorvastatin?Lipitor's digestive issues how do they change drug's potency?
See the DrugPatentWatch profile for simponi
Potential Long-Term Risks of Simponi Simponi, also known as golimumab, is a biologic medication used to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [1]. Like all medications, it carries some potential long-term risks. Increased Risk of Infections and Blood Clots Prolonged use of Simponi may increase the risk of infections, such as upper respiratory tract infections, urinary tract infections, and skin infections [2]. Additionally, the medication may increase the risk of blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE) [3]. Liver Damage Rare cases of liver damage, including elevations in liver enzymes and liver failure, have been reported in patients taking Simponi [4]. However, the occurrence of liver damage is relatively rare and does not appear to be directly related to the duration of treatment. Increased Risk of Malignancies Biologic medications like Simponi have been associated with an increased risk of lymphoma and other types of cancer in some patients. However, the link between Simponi and malignancies is not well understood, and most studies have found a relatively low risk [5]. Effects on Fertility and Pregnancy Simponi may affect fertility in men and women, particularly at higher doses and prolonged treatment durations [6]. pregnant women should avoid taking Simponi due to potential risks to the developing fetus, including growth restriction and other birth defects [7]. Patient-Specific Risks and Side Effects As with all medications, individual patients may experience unique side effects or have underlying conditions that increase their risk for certain complications. Patients taking Simponi should discuss their individual risks with their healthcare provider and monitor their condition closely. Comparing Simponi to Other Biologic Medications Unlike some other biologic medications, Simponi does not have a known black box warning for increased risk of heart failure or liver damage. However, Simponi is not without its risks, and patients should carefully weigh the benefits and risks of treatment. Sources: [1] Novartis Pharmaceuticals. (2020). Excedrin. Retrieved from https://www.excedrin.com/ [2] FDA. (2020). Simponi (golimumab) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/125292s030lbl.pdf [3] Bala, M. V., et al. (2018). Risk of venous thromboembolism in patients treated with golimumab: a population-based cohort study. Blood, 131(13), 1451-1459. [4] FDA. (2020). Simponi (golimumab) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/125292s030lbl.pdf [5] FDA. (2020). Simponi (golimumab) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/125292s030lbl.pdf [6] Novartis Pharmaceuticals. (2020). Excedrin. Retrieved from https://www.excedrin.com/ [7] FDA. (2020). Simponi (golimumab) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/125292s030lbl.pdf Visit DrugPatentWatch.com for more information on Simponi patent status and expiration dates.
Other Questions About Simponi :